CNBX Pharmaceuticals News
6 articles
growth-positive
CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel
CNBX Pharmaceuticals Inc., a global leader in the development of cancer-related cannabinoid-based medicine, has filed a patent application titled COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS with the US Patent and Trademark Office and the Israel Patent Office on October 12, 2022. The patent application is related to several drug candidates in the companys pipeline for treating various types of cancer. The companys growing IP portfolio includes 8 patent families, with 7 granted patents and 18 additional pending.
Customers
growth-positive
Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
Cannabics Pharmaceuticals Inc., a global leader in the development of cancer-related cannabinoid-based medicine, has announced a change in its corporate name to CNBX Pharmaceuticals Inc. The rebranding reflects the companys transformation and its forward-looking approach to molecule-based drug development for the treatment of colorectal cancer. The company is also preparing for a Phase I/II clinical validation study for its proprietary RCC-33 drug candidate. The companys stock will continue to trade under the ticker OTCQB: CNBX, and the change does not affect the rights of the companys stockholders.
Management Changes
growth-positive
Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis
Cannabics Pharmaceuticals Inc., a US-based company focused on personalized cannabinoid medicine for cancer, has received final approval from the Israeli government to export medical cannabis and products into international regulated markets such as the EU, Canada, and Australia. The new regulation will allow the export of GMP certified cannabis products under the Cannabics™ brand, such as Cannabics™ SR formulation, which has been tested as a palliative treatment for advanced cancer patients suffering from Cancer Anorexia-Cachexia Syndrome (CACS).
CustomersExpand
growth-positive
Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma
Cannabics Pharmaceuticals Inc., a leader in personalized cannabinoid medicine focused on cancer and its side effects, has completed a scan of selected RCKMCs cannabis strains. The results showed that two specific strains demonstrated higher anti-tumor activity. The strains were examined at the companys High Throughput Screening (HTS) facility located in Israel. The results will be used to further breed the selected cultivars for specific cancers, focusing on Gastric cancers. The cultivars to be developed will be the source for active pharmaceutical ingredients (APIs) for future clinical studies.
InvestmentExpand
Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization
growth-positive
Cannabics Pharmaceuticals Places IP & Subsidiary Within the Company
Cannabics Pharmaceuticals Inc. has announced that it has placed its wholly owned subsidiary Grin Ultra Ltd. and all accompanying Intellectual Property rights into its public company. The Intellectual Property involves the companys IP filed with the USPTO entitled A Method of in Vitro High Throughput Screening of Cancer Biopsies with Cannabinoid Extracts. This system analyzes cancer cells taken directly from patient biopsies, and then tests them against a multitude of cannabinoid combinations for anti-tumor activity. Grin Ultra Ltd. is specifically licensed by the Israeli Health Ministry for cannabinoid research.
Investment
